Kyowa Hakko Kirin Announces Approval of Darbepoetin Alfa Injection Syringe [KKF] in Japan
(WorldNews Japan)

August 16, 2018 (144KB) Tokyo, Japan, August 16, 2018 ---Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and COO: Masashi Miyamoto, `Kyowa Hakko Kirin`) announces today that its wholly owned subsidiary Kyowa Kirin Frontier Co., Ltd. (President and CEO: Wataru Murata, `Kyowa Kirin Frontier`) received manufacturing and marketing approval (MMA) in Japan on August 15 for `Darbepoetin Alfa Injection Syringe [KKF].` Darbepoetin Alfa is a Long-Acting...